Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025
I'm PortAI, I can summarize articles.
Sinopharm Group Co. Ltd. reported a decline in revenue and profits for its subsidiary, China National Accord Medicines Corporation Ltd. (Sinopharm Accord) for H1 2025. Revenue fell by 2.62% to 36.8 billion yuan, while net profit dropped by 10.43% to 665.9 million yuan. Operating cash flow decreased by 98.38%. However, total assets increased by 6.04% to over 50.4 billion yuan, and net assets attributable to shareholders rose by 2.64%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments